ABOUT

The proposed project is focusing the assessment of the antifungic effect of the inclusion complex of the propiconazole derivative and beta-cyclodextrin, determining the activity spectrum of the obtained nanoconjugates on clinical isolated fungi.

The activities performed within the project will successively determine the assessment of the in vitro antifungic effect of the propiconazole derivative both on type strains and clinical strains, in vivo assessment on experimental models and dissemination of results.

The experimental design will use testing standardized methods (eucast de.7.1, eucast def.9.1) that will provide reproducible results, allowing ulterior implementation in medical-pharmaceutical practice of the active substance.

The trials will be performed on a large variety of fungal species involved in current and emergent infectious pathology, on human and animals. Will be tested taxons belonging to candida, cryptococcus, malassezia, trichosporon, aspergillus, fusarium, scedosporium, absidia, rhizopus, epidermophyton, microsporum, trichophyton genera, which are dominating the etiological spectrum of mycosis in the last decade.

To establish the activity spectrum of the active substance, in vitro tests will be performed on levuriform and filamentous fungi strains isolated from superficial mycosis (of the skin and mucous membranes) and systemic (fungemias, profound infections), on human and animals. In vivo tests on murine experimental models with disseminated mycosis and fungi biofilms will determine the reduction degree of the fungic burden per gram of tissue, survival rate and decrease of the cfu number in biofilm after the therapy with nanoconjugates of the new antifungic substance.